CN1772885B - 诱导干细胞向胰岛样细胞分化的方法及胰岛样细胞的应用 - Google Patents
诱导干细胞向胰岛样细胞分化的方法及胰岛样细胞的应用 Download PDFInfo
- Publication number
- CN1772885B CN1772885B CN2004100907848A CN200410090784A CN1772885B CN 1772885 B CN1772885 B CN 1772885B CN 2004100907848 A CN2004100907848 A CN 2004100907848A CN 200410090784 A CN200410090784 A CN 200410090784A CN 1772885 B CN1772885 B CN 1772885B
- Authority
- CN
- China
- Prior art keywords
- cell
- glp
- stem cell
- gene
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 88
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims abstract description 21
- 230000001939 inductive effect Effects 0.000 title claims abstract description 9
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims abstract description 27
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 18
- 241000700605 Viruses Species 0.000 claims abstract description 14
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims abstract 7
- 238000001890 transfection Methods 0.000 claims description 24
- 230000002608 insulinlike Effects 0.000 claims description 22
- 230000004069 differentiation Effects 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 235000015097 nutrients Nutrition 0.000 claims description 18
- 108090001061 Insulin Proteins 0.000 claims description 17
- 210000004153 islets of langerhan Anatomy 0.000 claims description 16
- 102000004877 Insulin Human genes 0.000 claims description 15
- 210000004185 liver Anatomy 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 241000701161 unidentified adenovirus Species 0.000 claims description 10
- 210000004700 fetal blood Anatomy 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 230000024245 cell differentiation Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 210000000496 pancreas Anatomy 0.000 claims description 5
- 230000001177 retroviral effect Effects 0.000 claims description 5
- 102000051325 Glucagon Human genes 0.000 claims description 4
- 108060003199 Glucagon Proteins 0.000 claims description 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 4
- 229960004666 glucagon Drugs 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 210000003995 blood forming stem cell Anatomy 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 210000001178 neural stem cell Anatomy 0.000 claims description 3
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims description 2
- 108010021582 Glucokinase Proteins 0.000 claims description 2
- 102000030595 Glucokinase Human genes 0.000 claims description 2
- 108091052347 Glucose transporter family Proteins 0.000 claims description 2
- 102000005157 Somatostatin Human genes 0.000 claims description 2
- 108010056088 Somatostatin Proteins 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 2
- 229960000553 somatostatin Drugs 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 102100040918 Pro-glucagon Human genes 0.000 claims 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 9
- 238000012258 culturing Methods 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 4
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 239000003094 microcapsule Substances 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 21
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 13
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 230000000763 evoking effect Effects 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 238000001802 infusion Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 244000309466 calf Species 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 210000003240 portal vein Anatomy 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 4
- 101710144033 Pancreas/duodenum homeobox protein 1 Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000007877 drug screening Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000002734 Collagen Type VI Human genes 0.000 description 2
- 108010043741 Collagen Type VI Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000011177 media preparation Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100008044 Caenorhabditis elegans cut-1 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010063919 Glucagon Receptors Proteins 0.000 description 1
- 102100040890 Glucagon receptor Human genes 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 101150093388 MSC3 gene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 238000011053 TCID50 method Methods 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
基因 | 正义引物 | 反义引物 | 退火温度 | 长度 |
PDX-1 | CCCATGGATGAAGTCTACC | GTCCTCCTCCTT TTTCCAC | 52℃ | 262bp |
胰岛素 | ACCCAGCCGCAGCCTTTGTG | TTCCACAATGCCACGCTTCTGC | 56℃ | 223bp |
胰高血糖素样肽-1 | AGGCAGACCCACTCAGTGA | AACAATGGCGACCTCTTCTG | 56℃ | 308bp |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2004100907848A CN1772885B (zh) | 2004-11-11 | 2004-11-11 | 诱导干细胞向胰岛样细胞分化的方法及胰岛样细胞的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2004100907848A CN1772885B (zh) | 2004-11-11 | 2004-11-11 | 诱导干细胞向胰岛样细胞分化的方法及胰岛样细胞的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1772885A CN1772885A (zh) | 2006-05-17 |
CN1772885B true CN1772885B (zh) | 2010-12-01 |
Family
ID=36760025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004100907848A Expired - Fee Related CN1772885B (zh) | 2004-11-11 | 2004-11-11 | 诱导干细胞向胰岛样细胞分化的方法及胰岛样细胞的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1772885B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102311940A (zh) * | 2010-07-09 | 2012-01-11 | 中国人民解放军军事医学科学院野战输血研究所 | 诱导干细胞向胰岛样细胞分化的方法 |
CN103756954A (zh) * | 2014-01-22 | 2014-04-30 | 青岛中天干细胞工程有限公司 | 一种将人脂肪间充质干细胞诱导成胰岛素分泌细胞的诱导剂、诱导培养基及方法 |
CN104622901B (zh) * | 2015-01-09 | 2019-06-28 | 奥思达干细胞有限公司 | 一种人胚胎干细胞定向分化为造血干细胞的方法 |
CN104789520A (zh) * | 2015-03-10 | 2015-07-22 | 协和干细胞基因工程有限公司 | 利用脂肪间充质干细胞构建组织工程胰岛的方法及获得的组织工程胰岛 |
CN111875675B (zh) * | 2018-09-03 | 2021-10-01 | 广东新征程生命科学有限公司 | 表皮干细胞向胰腺细胞分化的改进方法 |
CN109336982B (zh) * | 2018-11-01 | 2020-10-09 | 长春万成生物电子工程有限公司 | 基因改造的干细胞及其应用 |
WO2022057903A1 (en) * | 2020-09-17 | 2022-03-24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric glp1r |
CN114908064A (zh) * | 2021-02-09 | 2022-08-16 | 南京惟亚德生物医药有限公司 | 一种能抑制肿瘤进展并延长荷瘤个体生存时间的复制型溶瘤腺病毒及其应用 |
-
2004
- 2004-11-11 CN CN2004100907848A patent/CN1772885B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1772885A (zh) | 2006-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1007631B2 (en) | Cardiac muscle regeneration using mesenchymal stem cells | |
US20070003530A1 (en) | Cardiac muscle regeneration using mesenchymal stem cells | |
CN101443023A (zh) | 使用脂肪组织来源的细胞治疗心血管病症的方法 | |
CN101437938A (zh) | 心脏干细胞 | |
CN103930542A (zh) | 棕色脂肪细胞组合物及方法 | |
CN102066555A (zh) | 用于治疗糖尿病的源自人脂肪组织的胰岛素生产性间充质干细胞 | |
CN110484566B (zh) | 一种类棕色脂肪外泌体及其工程化生产方法和应用 | |
CN110713984B (zh) | 诱导人间充质干细胞生成功能内皮细胞的方法 | |
CN114874982B (zh) | 一种增强脐带间充质干细胞分泌血管内皮生长因子的培养方法 | |
CN102517251A (zh) | 一种间充质干细胞及其制备方法和应用 | |
CN107460158A (zh) | 一种诱导脐带间充质干细胞分化为形成胰岛素的方法 | |
CN1772885B (zh) | 诱导干细胞向胰岛样细胞分化的方法及胰岛样细胞的应用 | |
US5453270A (en) | Pharmaceutical composition and method for hypermetabolic weight loss | |
CN108456655A (zh) | 间充质干细胞悬浮液及其制备方法与应用 | |
CA2183438A1 (en) | Method for preparing clonogenic fibroblasts, method for gene transfection of fibroblasts and gene-transfected fibroblasts so obtained | |
CN106434542A (zh) | 一种增强脂肪干细胞增殖与移植后存活能力的方法 | |
TWI263784B (en) | Encapsulated cell indicator system | |
CN113559273B (zh) | 一种静脉注射用成体干细胞的预处理方法、成体干细胞注射液及应用 | |
CN105456293A (zh) | 一种用于治疗糖尿病的干细胞制剂及其制备方法 | |
Day | Epithelial stem cells and tissue engineered intestine | |
CN113144221A (zh) | 外泌体制剂及其制备方法和应用 | |
CN101182493A (zh) | 一种治疗放射性肠炎的转基因间充质干细胞及其制备方法 | |
CN1637137A (zh) | 一种诱导干细胞向胰岛样细胞分化的方法及其应用 | |
CN101432420A (zh) | 用于血管生成治疗的自体或异源祖细胞的条件培养基 | |
CN108841786A (zh) | 人羊膜来源的间充质干细胞预处理方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20060517 Assignee: SOUTH CHINA CENTER FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE OF ACADEMY OF MILITARY MEDICAL SCIENCES Assignor: INSTITUE OF TRANSFUSION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBRATION ARMY OF CHINA Contract record no.: 2015990000123 Denomination of invention: Method of inducing stem cell to differentiate into pancreatic island-like cell and application of pancreatic island-like cell Granted publication date: 20101201 License type: Exclusive License Record date: 20150324 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101201 |